2023 - Research.com Medicine in Italy Leader Award
Michele Baccarani mainly investigates Internal medicine, Myeloid leukemia, Imatinib mesylate, Imatinib and Immunology. Her studies in Internal medicine integrate themes in fields like Gastroenterology, Surgery and Oncology. Her Myeloid leukemia research incorporates elements of Myeloid, Myelodysplastic syndromes, ABL and Phases of clinical research.
Her work deals with themes such as Survival rate, Tyrosine kinase, Alpha interferon and Young adult, which intersect with Imatinib mesylate. Her Imatinib research includes themes of Chronic myelogenous leukemia, Adverse effect, Philadelphia chromosome and Tyrosine-kinase inhibitor. Immunology is often connected to Neutropenia in her work.
Her primary areas of investigation include Internal medicine, Myeloid leukemia, Imatinib, Oncology and Immunology. Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Surgery. Her studies deal with areas such as Myeloid, Hematology and Leukemia as well as Myeloid leukemia.
Her Imatinib study combines topics from a wide range of disciplines, such as Discontinuation, Phases of clinical research, Adverse effect, Chronic myelogenous leukemia and Tyrosine-kinase inhibitor. Her Immunology research includes themes of Stem cell and Philadelphia chromosome. Her Nilotinib research integrates issues from Clinical trial and Pharmacology.
Her scientific interests lie mostly in Internal medicine, Myeloid leukemia, Oncology, Imatinib and Nilotinib. Imatinib mesylate, Dasatinib, Adverse effect, Ponatinib and Hematology are the core of her Internal medicine study. Her Myeloid leukemia research incorporates elements of Tyrosine kinase and Leukemia.
Her Oncology research focuses on Transplantation and how it connects with Stem cell. The study incorporates disciplines such as Clinical trial, Surgery, Philadelphia chromosome and Tyrosine-kinase inhibitor in addition to Imatinib. Her work deals with themes such as Incidence, Cumulative incidence, Discontinuation, Bristol-Myers and Pediatrics, which intersect with Nilotinib.
Her primary areas of investigation include Internal medicine, Myeloid leukemia, Imatinib, Oncology and Imatinib mesylate. Her Surgery research extends to Internal medicine, which is thematically connected. The various areas that Michele Baccarani examines in her Myeloid leukemia study include Young adult, Hematology, Prospective cohort study and Chronic myelogenous leukemia, Leukemia.
Her Imatinib study contributes to a more complete understanding of Immunology. Her Oncology study which covers Long term survival that intersects with Disease risk, Treatment strategy, Disease remission, MEDLINE and Chromosome 22. Her studies deal with areas such as Tyrosine kinase, Cancer and Alpha interferon as well as Imatinib mesylate.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop Kantarjian;Neil P. Shah;Andreas Hochhaus;Jorge Cortes.
The New England Journal of Medicine (2010)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus.
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser.
Journal of Clinical Oncology (2009)
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
JE Sokal;EB Cox;M Baccarani;S Tura.
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo;Paola Tacchetti;Francesca Patriarca;Maria Teresa Petrucci.
The Lancet (2010)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford.
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre.
The New England Journal of Medicine (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: